• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Inspira Technologies Oxy B.H.N. Ltd.

    1/6/26 5:25:19 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care
    Get the next $IINN alert in real time by email
    S-8 1 ea0272007-s8_inspira.htm REGISTRATION STATEMENT

    As filed with the Securities and Exchange Commission on January 6, 2026

    Registration No. 333 -  

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

    (Exact name of registrant as specified in its charter)

     

    State of Israel   Not applicable
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification No.)

     

    2 Ha-Tidhar St., Ra’anana, 4366504 Israel

    (Address of Principal Executive Offices)

     

    Inspira Technologies OXY B.H.N. LTD.

    Amended and Restated 2019 Equity Incentive Plan

    (Full title of the plan)

     

    Puglisi & Associates

    850 Library Ave., Suite 204, Newark, DE 19711

    Tel: (302) 738-6680

    (Name, Address and Telephone Number of Agent for Service)

     

    COPIES TO:

     

    Oded Har-Even, Esq.

    Ron Ben-Bassat, Esq.

    Sullivan & Worcester LLP

    1251 Avenue of the Americas

    New York, NY 10020

    Tel: (212)-660-3000

    Adv. Reut Alfiah

    Adv. Gal Cohen

    Sullivan & Worcester Tel-Aviv (Har-Even & Co.)

    28 HaArba’a St. HaArba’a Towers

    North Tower, 35th floor

    Tel-Aviv, Israel 6473925

    Tel: +972 74-758-0480

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐   Accelerated filer ☐
    Non-accelerated filer ☒   Smaller reporting company ☐
        Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    On August 5, 2021, Inspira Technologies Oxy B.H.N. Ltd., or the Registrant or the Company, filed a Registration Statement on Form S-8 (File No. 333-259057), or the Original Registration Statement, with the Securities and Exchange Commission, or the SEC, to register an aggregate of 4,180,898 ordinary shares, no par value per share, of the Company, or the Ordinary Shares, that may be issued pursuant to the Company’s 2019 Equity Incentive Plan, or the 2019 Plan. On March 15, 2024, the Company filed an additional Registration Statement on Form S-8 (File No. 333-277980) with the SEC to register an additional 2,997,671 Ordinary Shares that may be issued pursuant to the 2019 Plan. On March 5, 2025, the Company filed an additional Registration Statement on Form S-8 (File No. 333-285565) with the SEC to register an additional 3,000,000 Ordinary Shares that may be issued pursuant to the 2019 Plan. On September 10, 2025, the Company filed an additional Registration Statement on Form S-8 (File No. 333-290162) with the SEC to register an additional 1,184,910 Ordinary Shares that may be issued pursuant to the 2019 Plan.

     

    The 2019 Plan was originally adopted by the board of directors of the Company in November 2019, amended in September 2021, and further amended and restated in March 2025, or the Amended and Restated 2019 Plan.

     

    The Company is filing this Registration Statement on Form S-8, or this Registration Statement, to register an additional 512,498 Ordinary Shares reserved for issuance in connection with securities awards which may hereafter be granted under the Amended and Restated 2019 Plan.

     

    Pursuant to General Instruction E to Form S-8, the contents of the Original Registration Statement are incorporated herein by reference, except for Items 3 and 8 of Part II of the Original Registration Statement, which are being updated by this Registration Statement.

     

     

     

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the Plan covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act of 1933, as amended, or the Securities Act.

     

    1

     

     

    PART II

     

    ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE

     

    The following documents filed by the Company with the SEC are incorporated by reference into this Registration Statement:

     

    ●Our Annual Report on Form 20-F for the fiscal year ended December 31, 2024, filed with the SEC on March 10, 2025 and as amended on March 28, 2025;

     

      ● Our Reports on Form 6-K furnished on March 11, 2025 (with respect to the first paragraph, the sections titled “Recent Business and Operational Highlights,” “Full Year 2024 Financial Results” and “Forward-Looking Statements” of the press release attached therewith as Exhibit 99.1), March 13, 2025, March 14, 2025, March 14, 2025, March 25, 2025 (with respect to the first, second, fourth, and fifth paragraphs and the section titled “Forward-Looking Statements”), April 7, 2025 (with respect to the first, second, and fifth paragraphs and the section titled “Forward-Looking Statements”), April 10, 2025, April 15, 2025 (with respect to the first, second, and fourth paragraphs and the section titled “Forward-Looking Statements”), April 23, 2025 (with respect to the first three and fifth paragraphs and the section titled “Forward-Looking Statements”), May 7, 2025 (with respect to the first three and fifth paragraphs and the section titled “Forward-Looking Statements”), May 12, 2025, May 27, 2025 (with respect to the first, second, fifth and sixth paragraphs and the section titled “Forward-Looking Statements”), May 29, 2025 (with respect to the first, second, fourth, fifth and sixth paragraphs and the section titled “Forward-Looking Statements”), May 30, 2025, June 5, 2025 (with respect to the first, second, fourth and fifth paragraphs and the section titled “Forward-Looking Statements”), June 11, 2025, June 23, 2025, July 1, 2025, July 2, 2025 (with respect to the first, second, and fifth paragraphs and the section titled “Forward-Looking Statements”), July 7, 2025 (with respect to the first three paragraphs and the section titled “Forward-Looking Statements”), July 10, 2025 (with respect to the first two paragraphs and the section titled “Forward-Looking Statements”), July 17, 2025, July 18, 2025 (with respect to the first two paragraphs and the section titled “Forward-Looking Statements”), July 31, 2025 (with respect to the first, second, and fourth paragraphs and the section titled “Forward-Looking Statements”); August 19, 2025 (with respect to the first, second, and fourth paragraphs and the section titled “Forward-Looking Statements”), August 22, 2025 (with respect to the first, second, and fourth paragraphs and the section titled “Forward-Looking Statements”)  September 2, 2025 (with respect to the first, second, and fourth paragraphs and the section titled “Forward-Looking Statements”);  September 11, 2025 (with respect to the first four paragraphs and the section titled “Forward-Looking Statements”), September 16, 2025; September 18, 2025 (with respect to the first, second, third and fifth paragraphs and the section titled “Forward-Looking Statements”), October 1, 2025; October 21, 2025 (with respect to the first, second and third paragraphs and the section titled “Forward-Looking Statements”), October 22, 2025 (with respect to the first four paragraphs and the section titled “Forward-Looking Statements”), November 6, 2025 (with respect to the first, second, and fourth paragraphs and the section titled “Forward-Looking Statements” ), November 13, 2025 (with respect to the first three and the fifth paragraphs and the section titled “Forward-Looking Statements”), November 25, 2025, December 3, 2025 (with respect to the first four and the sixth paragraphs and the section titled “Forward-Looking Statements”), December 9, 2025 (with respect to the first three paragraphs and the section titled “Forward-Looking Statement Disclaimer”) December 15, 2025; December 23, 2025; December 31, 2025; and January 5, 2026; and

     

    ●The description of our securities contained in Exhibit 2.1 to our Annual Report on Form 20-F for the fiscal year ended December 31, 2024, filed with the SEC on March 10, 2025, and as amended on March 28, 2025.

     

    II-1

     

     

    In addition to the foregoing, all documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act and all reports on Form 6-K subsequently filed by the Registrant which state that they are incorporated by reference herein, prior to the filing of a post-effective amendment which indicates that all securities offered hereunder have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing of such documents and reports.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein, or in any subsequently filed document which also is or is deemed to be incorporated by reference, modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    ITEM 6.  INDEMNIFICATION OF DIRECTORS AND OFFICERS

     

    Indemnification

     

    The Israeli Companies Law, 5759-1999, or the Companies Law, and the Israeli Securities Law, 5728-1968, or the Securities Law, provide that a company may indemnify an office holder against the following liabilities and expenses incurred for acts performed by him or her as an office holder, either pursuant to an undertaking made in advance of an event or following an event, provided its articles of association include a provision authorizing such indemnification:

     

      ● a financial liability imposed on him or her in favor of another person by a judgment concerning an act performed in his or her capacity as an office holder, including a settlement or arbitrator’s award approved by a court;
         
      ● reasonable litigation expenses, including attorneys’ fees, expended by the office holder (a) as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that  (1) no indictment was filed against such office holder as a result of such investigation or proceeding; and (2) no financial liability as a substitute for the criminal proceeding (as defined in the Companies Law) was imposed upon him or her as a result of such investigation or proceeding, or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent; or (b) in connection with a monetary sanction;
         
      ● reasonable litigation expenses, including attorneys’ fees, expended by the office holder or imposed on him or her by a court: (1) in proceedings that the company institutes, or that are instituted on the company’s behalf, or by another person, against him or her; (2) in a criminal proceeding of which he or she was acquitted; or (3) as a result of a conviction for a crime that does not require proof of criminal intent; and
         
      ● expenses incurred by an office holder in connection with an Administrative Procedure under the Securities Law, including reasonable litigation expenses and reasonable attorneys’ fees. An “Administrative Procedure” is defined as a procedure pursuant to chapters H3 (Monetary Sanction by the Israeli Securities Authority), H4 (Administrative Enforcement Procedures of the Administrative Enforcement Committee) or I1 (Arrangement to prevent Procedures or Interruption of procedures subject to conditions) to the Securities Law.

     

    The Companies Law also permits, if a company adds provisions in the articles of association, to undertake in advance to indemnify an office holder, provided that if such indemnification relates to financial liability imposed on him or her, as described above, then the undertaking should be limited and shall detail the following foreseen events and amount or criterion:

     

      ● to events that in the opinion of the board of directors can be foreseen based on the company’s activities at the time that the undertaking to indemnify is made; and
         
      ● in amount or criterion determined by the board of directors, at the time of the giving of such undertaking to indemnify, to be reasonable under the circumstances.

     

    II-2

     

     

    We have entered into indemnification agreements with all of our directors and with all members of our senior management. Each such indemnification agreement provides the office holder with indemnification permitted under applicable law and up to a certain amount, and to the extent that these liabilities are not covered by directors’ and officers’ insurance.

     

    Insurance

     

    Under the Companies Law, a company may obtain insurance for any of its office holders against the following liabilities incurred due to acts he or she performed as an office holder, if and to the extent provided for in the company’s articles of association:

     

      ● breach of his or her duty of care to the company or to another person, to the extent such a breach arises out of the negligent conduct of the office holder;

     

      ● a breach of his or her duty of loyalty to the company, provided that the office holder acted in good faith and had reasonable cause to assume that his or her act would not prejudice the company’s interests; and
         
      ● a financial liability imposed upon him or her in favor of another person.

     

    Exemption

     

    Under the Companies Law, an Israeli company may not exempt an office holder from liability for a breach of his or her duty of loyalty, but may exempt in advance an office holder from his or her liability to the company, in whole or in part, for damages caused to the company as a result of a breach of his or her duty of care (other than in relation to distributions), but only if a provision authorizing such exemption is included in its articles of association. Our amended and restated articles of association and our indemnification agreements provide that we may exempt, in whole or in part, any office holder from liability to us for damages caused to the company as a result of a breach of his or her duty of care. Subject to the aforesaid limitations, under the indemnification agreements, we exempt and release our office holders from any and all liability to us related to any breach by them of their duty of care to us to the fullest extent permitted by law, while acting in good faith and having reasonable cause to assume that such act or omission would not prejudice the interests of the Company, provided that the indemnitee shall not be exempt with respect to any action or omission as to which, under applicable law, the Company is not entitled to exempt the indemnitee.

      

    Limitations

     

    The Companies Law provides that the Company may not exempt or indemnify an office holder nor enter into an insurance contract that would provide coverage for any liability incurred as a result of any of the following: (1) a breach by the office holder of his or her duty of loyalty unless (in the case of indemnity or insurance only, but not exemption) the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice us; (2) a breach by the office holder of his or her duty of care if the breach was carried out intentionally or recklessly (as opposed to merely negligently); (3) any act or omission committed with the intent to derive an illegal personal benefit; or (4) any fine, monetary sanction, penalty or forfeit levied against the office holder.

     

    Under the Companies Law, exemption, indemnification and insurance of office holders in a public company must be approved by the compensation committee and the board of directors )and, with respect to directors and the chief executive officer, by the shareholders). However, under regulations promulgated under the Companies Law, the insurance of office holders shall not require shareholder approval and may be approved by only the compensation committee, if the engagement terms are determined in accordance with the company’s compensation policy that was approved by the shareholders by the same special majority required to approve a compensation policy, provided that the insurance policy is on market terms and the insurance policy is not likely to materially impact the company’s profitability, assets or obligations. In addition, under regulations promulgated under the Companies Law, the insurance of office holders of a company in which there is a controlling shareholder who is also an office holder, a board approval is also required, subject to meeting the aforesaid conditions.

     

    II-3

     

     

    Our amended and restated articles of association permit us to exempt (subject to the aforesaid limitation), indemnify and insure our office holders to the fullest extent permitted or to be permitted by the Companies Law.

     

    Item 8.   Exhibits.
    4.1   Amended and Restated Articles of Association of Inspira Technologies Oxy B.H.N. Ltd. (incorporated by reference to Exhibit 99.1 to the Company’s Report on Form 6-K (File No. 001-40303) filed on December 20, 2021).
         
    5.1*   Opinion of Sullivan & Worcester Tel Aviv (Har-Even & Co.)
         
    23.1*   Consent of Ziv Haft, member firm of BDO, independent registered public accounting firm.
         
    23.2*   Consent of Sullivan & Worcester Tel Aviv (Har-Even & Co.) (included in the opinion filed as Exhibit 5.1 to this Registration Statement)
         
    24.1*   Power of Attorney (included on signature page)
         
    99.1   Amended and Restated Inspira Technologies Oxy B.H.N. Ltd. 2019 Equity Incentive Plan (incorporated by reference to Exhibit 99.1 to the Company’s Form S-8 (File No. 333-285565) filed on March 5, 2025).
         
    107*   Filing Fee Table.

     

    *Filed herewith.

     

    II-4

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in Ra’anana, Israel, on January 6, 2026.

     

      INSPIRA TECHNOLOGIES OXY B.H.N. LTD.
         
      By: /s/ Dagi Ben-Noon
        Name:  Dagi Ben-Noon
        Title: Chief Executive Officer

     

    POWER OF ATTORNEY AND SIGNATURES

     

    We, the undersigned officers and directors of Inspira Technologies Oxy B.H.N. Ltd., hereby severally constitute and appoint Dagi Ben-Noon and Yafit Tehila, and each of them individually, our true and lawful attorney to sign for us and in our names in the capacities indicated below any and all amendments or supplements, including any post-effective amendments, to this Registration Statement on Form S-8 and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming our signatures to said amendments to this Registration Statement signed by our said attorney and all else that said attorney may lawfully do and cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act, this Registration Statement on Form S-8 has been signed below by the following persons in the capacities and on the dates indicated.

     

    Signature    Title    Date 
             
    /s/ Dagi Ben-Noon   Chief Executive Officer and Director   January 6, 2026
    Dagi Ben-Noon   (Principal Executive Officer)    
             
    /s/ Yafit Tehila   Chief Financial Officer   January 6, 2026
    Yafit Tehila   (Principal Financial and Accounting Officer)    
             
    /s/ Tal Parnes   Chairman of the Board of Directors   January 6, 2026
    Tal Parnes        
             
    /s/ Lior Amit   Director   January 6, 2026
    Lior Amit        
             
    /s/ Sivan Matza   Director   January 6, 2026
    Sivan Matza        

     

    II-5

     

     

    SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES

     

    Pursuant to the Securities Act, the undersigned, Puglisi & Associates, the duly authorized representative in the United States of Inspira Technologies Oxy B.H.N. Ltd., has signed this Registration Statement on Form S-8 on January 6, 2026.

     

      Puglisi & Associates
       
      Authorized U.S. Representative
       
      /s/ Donald J. Puglisi
      Name:  Donald J. Puglisi
      Title: Managing Director

     

    II-6

     

     

     

     

     

     

    Get the next $IINN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IINN

    DatePrice TargetRatingAnalyst
    11/1/2021$9.00 → $10.00Buy
    Aegis Capital
    8/26/2021$9.00Buy
    Aegis Capital
    More analyst ratings

    $IINN
    SEC Filings

    View All

    SEC Form 6-K filed by Inspira Technologies Oxy B.H.N. Ltd.

    6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)

    2/9/26 6:42:15 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by Inspira Technologies Oxy B.H.N. Ltd.

    6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)

    2/6/26 9:20:54 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    SEC Form 424B5 filed by Inspira Technologies Oxy B.H.N. Ltd.

    424B5 - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)

    2/6/26 9:00:38 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    $IINN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Inspira Secures Vendor Approval from $12 Billion Revenue HMO (World's 2nd Largest), Enabling Immediate ART100 Deployment

    RA'ANANA, Israel, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW)) ("Inspira Technologies" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced a pivotal commercial advancement. The Company has received official approval from the Medical Equipment Committee of Clalit Health Services ("Clalit"), recognized as the second-largest integrated Health Maintenance Organization (HMO) globally. The approval enables the INSPIRA™ ART100 system for immediate procurement and operational use across Clalit's extensive medical ecosystem. Key Highlights: Commercial Activation: The approval transitions the ART100 f

    2/9/26 7:00:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    Inspira Announces Pricing of $4.75 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules

    RA'ANANA, Israel, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW)) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it has entered into a definitive agreement with a single healthcare-focused, institutional investor for a registered direct offering priced at-the-market under Nasdaq Rules of an aggregate of 6,785,715 ordinary shares (or ordinary share equivalents in lieu thereof) at a purchase price of $0.70 per share. The gross proceeds to the Company from the offering are expected to be approximately $4.75 million, before deducting placement agent commi

    2/5/26 8:00:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    Inspira Technologies Validates Next-Gen Standalone HYLA™ Blood Sensor with Clinical-Grade Accuracy, Targeting $48 Billion Heart-Lung Surgery Market

    RA'ANANA, Israel, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW)) ("Inspira Technologies" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced the successful validation in the Company's advanced blood labs of its Next-Generation Standalone HYLA™ System. Designed to function independently of the Company's respiratory support devices, this new configuration allows Inspira Technologies to penetrate the broader approximately $50 billion heart-lung surgery market immediately upon clearance. In advanced bench testing, the system demonstrated 94.2% accuracy for the continuous optical measurement of Parti

    2/3/26 9:22:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    $IINN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Aegis Capital reiterated coverage on Inspira Technologies Oxy with a new price target

    Aegis Capital reiterated coverage of Inspira Technologies Oxy with a rating of Buy and set a new price target of $10.00 from $9.00 previously

    11/1/21 12:39:26 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    Aegis Capital initiated coverage on Inspira Technologies Oxy with a new price target

    Aegis Capital initiated coverage of Inspira Technologies Oxy with a rating of Buy and set a new price target of $9.00

    8/26/21 10:05:11 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    $IINN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Inspira Technologies Oxy B.H.N. Ltd.

    SC 13G/A - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)

    11/14/24 4:08:42 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Inspira Technologies Oxy B.H.N. Ltd.

    SC 13G - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)

    2/14/24 3:40:01 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Inspira Technologies Oxy B.H.N. Ltd. (Amendment)

    SC 13G/A - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)

    2/12/24 4:05:09 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    $IINN
    Leadership Updates

    Live Leadership Updates

    View All

    Inspira Appoints Former Johnson & Johnson Senior Business Manager as VP of Global Sales and New Board Member from a Leading International Investment Firm

    RA'ANANA, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced two key leadership appointments that reinforce its global commercialization and governance – the appointment of Mr. Mike Hershkovitz as Vice President of Global Sales of the Company and the appointment of Ms. Sivan Matza as a member of the board of directors of the Company (the "Board"). The Board appointed Ms. Matza to serve as an independent director of the Company until the next annual general meeting of the Company's shareholders. Ms. Matza will als

    10/21/25 3:40:00 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    Inspira Appoints Former Johnson & Johnson Executive as VP of Global Sales and New Board Member from a Leading International Investment Firm

    RA'ANANA, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced two key leadership appointments that reinforce its global commercialization and governance – the appointment of Mr. Mike Hershkovitz as Vice President of Global Sales of the Company and the appointment of Ms. Sivan Matza as a member of the board of directors of the Company (the "Board"). The Board appointed Ms. Matza to serve as an independent director of the Company until the next annual general meeting of the Company's shareholders. Ms. Matza will als

    10/21/25 9:05:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    PESG Report: Inspira Technologies Strengthens its AI-Powered Blood Sensor with new Capabilities, Intends to Share Clinical Findings Soon

    Inspira Technologies* advancement of its AI-powered blood monitoring technology comes amid robust growth in medical technology M&A, with Q3 2024 seeing 275 deals worth $34 billion - a 35% increase year-over-year. The integration of this new oxygenation indicator strengthens the Company's position in both the $2.5 billion blood gas analysis market and, through the FDA-cleared INSPIRA ART100 system, the $19 billion mechanical ventilation market. With clinical evaluations of the HYLA blood sensor underway at Sheba Medical Center and preliminary results reportedly expected in the near future, the Company continues to execute its strategy of combining AI-enhanced monitoring capabilities with inn

    2/6/25 8:27:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    $IINN
    Financials

    Live finance-specific insights

    View All

    Inspira Outlines Strategic Vision and Transaction Framework for Breast Cancer Liquid Biopsy Expansion

    RA'ANANA, Israel, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today outlines its strategic vision and proposed transaction framework for its planned expansion into liquid biopsy diagnostics, outlining a structured approach designed to preserve shareholder value while enabling future dividend distributions the Company's core respiratory and life-support technologies. This framework underpins a proposed acquisition of an advanced liquid biopsy platform alongside a concurrent equity investment (the "Equity Investment"), positioning

    1/8/26 8:50:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    Inspira Technologies Reports First Half 2025 Financial Results and Issues Business Update

    RA'ANANA, Israel, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW)) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced its financial results for the six-month period ended June 30, 2025, and issued a business update. "The first half of 2025 represents a pivotal transformation for Inspira as we have successfully transitioned from being a development-stage company to commencing commercial execution. Our technology is now saving lives in premier U.S. hospitals while generating growing commercial interest globally," said Dagi Ben-Noon, Chief Executive Officer of Inspira. "With $49.5 millio

    10/1/25 8:00:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    Inspira Technologies Reports Full Year 2024 Financial Results and Provides Business Updates

    Significant progress in HYLA blood sensor and INSPIRA ART core technologies RA'ANANA, Israel, March 11, 2025 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced its financial results for the full year ended December 31, 2024, and provided a corporate update. Dagi Ben-Noon, Chief Executive Officer of Inspira, commented: "2024 was a transformative year for Inspira, marked by significant technological advancements and a major regulatory milestone. We successfully obtained 510(k) clearance from the Food and Drug Administration ("FDA") for our INSPIRA™ ART100 system an

    3/11/25 8:30:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care